SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on July 5, 2002; DOI 10.1182/blood-2002-02-0352. This Article Full Text (PDF) All Versions of this Article: 2002-02-0352v1 100/9/3141    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Avvisati, G. Articles by Mandelli, F. Search for Related Content PubMed PubMed Citation Articles by Avvisati, G. Articles by Mandelli, F. Social Bookmarking                   What's this? Submitted February 5, 2002 Accepted June 13, 2002 Induction therapy with idarubicin alone significantly influences the event-free survival (EFS) duration of newly-diagnosed hypergranular acute promyelocytic leukemia patients: final results of the GIMEMA randomized study 'LAP 0389' with 7 years of minimal follow-up Giuseppe Avvisati*, Maria Concetta Petti, Francesco Lo Coco, Maria Luce Vegna, Sergio Amadori, Michele Baccarani, Nicola Cantore, Eros Di Bona, Felicetto Ferrara, Giuseppe Fioritoni, Eugenio Gallo, Rosangela Invernizzi, Mario Lazzarino, Vincenzo Liso, Guglielmo Mariani, Francesco Ricciuti, Carmine Selleri, Simona Sica, Dino Veneri, and Franco Mandelli Ematologia, Universita Campus-Bio-Medico, Rome, Italy SC Ematologia, Istituto Regina Elena, Rome, Italy Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita la Sapienza, Policlinico Umberto 1, Rome, Italy Ematologia, Universita Tor Vergata, Ospedale S. Eugenio, Rome, Italy Istituto di Ematologia ed Oncologia Medica L.e A. Seragnoli, Universita di Bologna, Bologna, Italy Divisione di Ematologia, Ospedale Civile, Avellino, Italy Divisione di Ematologia, Ospedale S. Bortolo, Vicenza, Italy Divisione di Ematologia, Ospedale A.Cardarelli, Naples, Italy Divisione di Ematologia, Ospedale Civile, Pescara, Italy Divisione di Ematologia, Ospedale S. Giovanni Battista, Turin, Italy Istituto di Clinica Medica, Universita di Pavia, Policlinico Universitario, IRCCS S. Matteo, Pavia, Italy Cattedra di Ematologia, Universita di Pavia, Policlinico Universitario, IRCCS S. Matteo, Pavia, Italy Ematologia, Universita degli Studi, Policlinico Universitario, Bari, Italy Cattedra di Ematologia, Universita degli Studi, Palermo, Italy Divisione di Ematologia, Ospedale S. Carlo, Potenza, Italy Ematologia, Universita Federico II, Policlinico Universitario, Naples, Italy Ematologia, Universita Cattolica del Sacro Cuore, Policlinico Gemelli, Rome, Italy Ematologia, Universita degli Studi, Ospedale Policlinico Borgo Roma, Verona, Italy * Corresponding author; email: g.avvisati{at}unicampus.it. Shortly before the ATRA era, the GIMEMA cooperative group initiated a randomized study comparing, IDA alone vs IDA + ARA-C as induction treatment in newly diagnosed hypergranular APL patients. Of the 257 patients evaluable for the induction treatment, 131 were randomized to receive IDA alone (Arm A) and 126 to receive IDA + ARA-C (Arm B). Treatment in Arm A consisted of IDA 10mg/m2 daily for 6 consecutive days while in arm B it consisted of IDA 12 mg/m2 daily for 4 days combined with ARA-C 200 mg/m2 daily in continuous infusion for 7 days. Once in CR, patients received three consolidation courses of standard chemotherapy and those still in CR at the end of the consolidation were randomized to receive or not 6-mercaptopurine (1mg/Kg daily) and weekly intramuscular injections of methotrexate (0.25 mg /Kg) for a period of two years. Overall, 100 patients (76.3%) in Arm A, and 84 (66.6%) in Arm B, achieved CR (P = NS). EFS was 35% and 23% for patients in arm A and B respectively (P = 0.0429). The multivariate analysis revealed that EFS was favorably influenced by induction treatment with IDA alone (P=0.0101) and unfavorably influenced by WBC>3,000/µL (P=0.0001) and increasing age (P= 0.0251). These results, indicate that the anthracycline monochemotherapy with Idarubicin favourably influence the EFS of newly diagnosed hypergranular APL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. Kelaidi, S. Chevret, S. De Botton, E. Raffoux, A. Guerci, X. Thomas, A. Pigneux, T. Lamy, F. Rigal-Huguet, S. Meyer-Monard, et al. Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience J. Clin. Oncol., June 1, 2009; 27(16): 2668 - 2676. [Abstract] [Full Text] [PDF] M. A. Sanz, D. Grimwade, M. S. Tallman, B. Lowenberg, P. Fenaux, E. H. Estey, T. Naoe, E. Lengfelder, T. Buchner, H. Dohner, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, February 26, 2009; 113(9): 1875 - 1891. [Abstract] [Full Text] [PDF] L. Ades, M. A. Sanz, S. Chevret, P. Montesinos, P. Chevallier, E. Raffoux, E. Vellenga, A. Guerci, A. Pigneux, F. Huguet, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results Blood, February 1, 2008; 111(3): 1078 - 1084. [Abstract] [Full Text] [PDF] M. S. Tallman and J. K. Altman Curative Strategies in Acute Promyelocytic Leukemia Hematology, January 1, 2008; 2008(1): 391 - 399. [Abstract] [Full Text] [PDF] N. Asou, Y. Kishimoto, H. Kiyoi, M. Okada, Y. Kawai, M. Tsuzuki, K. Horikawa, M. Matsuda, K. Shinagawa, T. Kobayashi, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RAR{alpha} transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study Blood, July 1, 2007; 110(1): 59 - 66. [Abstract] [Full Text] [PDF] L. Ades, S. Chevret, E. Raffoux, S. de Botton, A. Guerci, A. Pigneux, A. M. Stoppa, T. Lamy, F. Rigal-Huguet, A. Vekhoff, et al. Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group J. Clin. Oncol., December 20, 2006; 24(36): 5703 - 5710. [Abstract] [Full Text] [PDF] E. J. Jabbour, E. Estey, and H. M. Kantarjian Adult Acute Myeloid Leukemia Mayo Clin. Proc., February 1, 2006; 81(2): 247 - 260. [Abstract] [Full Text] [PDF] M. A. Sanz Treatment of Acute Promyelocytic Leukemia Hematology, January 1, 2006; 2006(1): 147 - 155. [Abstract] [Full Text] [PDF] M. A. Sanz, M. S. Tallman, and F. Lo-Coco Practice Points, Consensus, and Controversial Issues in the Management of Patients with Newly Diagnosed Acute Promyelocytic Leukemia Oncologist, November 1, 2005; 10(10): 806 - 814. [Abstract] [Full Text] [PDF] A. M. Testi, A. Biondi, F. L. Coco, M. L. Moleti, F. Giona, M. Vignetti, G. Menna, F. Locatelli, A. Pession, E. Barisone, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children Blood, July 15, 2005; 106(2): 447 - 453. [Abstract] [Full Text] [PDF] Z.-X. Shen, Z.-Z. Shi, J. Fang, B.-W. Gu, J.-M. Li, Y.-M. Zhu, J.-Y. Shi, P.-Z. Zheng, H. Yan, Y.-F. Liu, et al. Inaugural Article: All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia PNAS, April 13, 2004; 101(15): 5328 - 5335. [Abstract] [Full Text] [PDF] B. Lowenberg, J. D. Griffin, and M. S. Tallman Acute Myeloid Leukemia and Acute Promyelocytic Leukemia Hematology, January 1, 2003; 2003(1): 82 - 101. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020